newsfilter
← Latest News
GlobeNewswire·

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

Adverse events (AEs) generally transient and readily manageable; only 2 cases of cytokine release syndrome (CRS)Prolonged tumor control with increasing doses of BA3182; confirmed partial response (cPR) at 0.6 mg in a